## Pedro J Caraballo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1940784/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Preemptive Genotyping for Personalized Medicine: Design of the Right Drug, Right Dose, Right Time—Using Genomic Data to Individualize Treatment Protocol. Mayo Clinic Proceedings, 2014, 89, 25-33.	3.0	250
2	Preemptive Pharmacogenomic Testing for Precision Medicine. Journal of Molecular Diagnostics, 2016, 18, 438-445.	2.8	171
3	Institution-Wide QT Alert System Identifies Patients With a High Risk of Mortality. Mayo Clinic Proceedings, 2013, 88, 315-325.	3.0	133
4	Multidisciplinary model to implement pharmacogenomics at the point of care. Genetics in Medicine, 2017, 19, 421-429.	2.4	74
5	Integrating Pharmacogenomics into Clinical Practice: Promise vs Reality. American Journal of Medicine, 2016, 129, 1093-1099.e1.	1.5	67
6	Participant-perceived understanding and perspectives on pharmacogenomics: the Mayo Clinic RIGHT protocol (Right Drug, Right Dose, Right Time). Genetics in Medicine, 2017, 19, 819-825.	2.4	50
7	Type 2 Diabetes Mellitus Trajectories and Associated Risks. Big Data, 2016, 4, 25-30.	3.4	46
8	Extending Association Rule Summarization Techniques to Assess Risk of Diabetes Mellitus. IEEE Transactions on Knowledge and Data Engineering, 2015, 27, 130-141.	5.7	44
9	The challenges of implementing pharmacogenomic testing in the clinic. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 567-577.	1.4	37
10	Impact of clinical decision support preventing the use of QT-prolonging medications for patients at risk for torsade de pointes. Journal of the American Medical Informatics Association: JAMIA, 2015, 22, e21-e27.	4.4	35
11	Cohort Profile: The Right Drug, Right Dose, Right Time: Using Genomic Data to Individualize Treatment Protocol (RIGHT Protocol). International Journal of Epidemiology, 2020, 49, 23-24k.	1.9	34
12	The Return of Actionable Variants Empirical (RAVE) Study, a Mayo Clinic Genomic Medicine Implementation Study: Design and Initial Results. Mayo Clinic Proceedings, 2018, 93, 1600-1610.	3.0	29
13	Integrating pharmacogenomics into the electronic health record by implementing genomic indicators. Journal of the American Medical Informatics Association: JAMIA, 2020, 27, 154-158.	4.4	29
14	Pharmacogenomic clinical decision support design and multi-site process outcomes analysis in the eMERGE Network. Journal of the American Medical Informatics Association: JAMIA, 2019, 26, 143-148.	4.4	28
15	Implementation of preemptive DNA sequence–based pharmacogenomics testing across a large academic medical center: The Mayo-Baylor RIGHT 10K Study. Genetics in Medicine, 2022, 24, 1062-1072.	2.4	28
16	Statin Use, Diabetes Incidence and Overall Mortality in Normoglycemic and Impaired Fasting Glucose Patients. Journal of General Internal Medicine, 2016, 31, 502-508.	2.6	23
17	Prevalence and Outcome of High-Risk QT Prolongation Recorded in the Emergency Department from an Institution-Wide QT Alert System. Journal of Emergency Medicine, 2018, 54, 8-15.	0.7	23
18	An Automated Clinical Alert System for Newly-Diagnosed Atrial Fibrillation. PLoS ONE, 2015, 10, e0122153.	2.5	22

PEDRO J CARABALLO

#	Article	IF	CITATIONS
19	<em>CYP2D6</em> phenotypes are associated with adverse outcomes related to opioid medications. Pharmacogenomics and Personalized Medicine, 2017, Volume 10, 217-227.	0.7	22
20	Challenges in Ordering and Interpreting Pharmacogenomic Tests in Clinical Practice. American Journal of Medicine, 2017, 130, 1342-1344.	1.5	21
21	Empowering genomic medicine by establishing critical sequencing result data flows: the eMERGE example. Journal of the American Medical Informatics Association: JAMIA, 2018, 25, 1375-1381.	4.4	21
22	A Clinical Decision Support Tool for Familial Hypercholesterolemia Based on Physician Input. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2018, 2, 103-112.	2.4	19
23	Towards more Accessible Precision Medicine: Building a more Transferable Machine Learning Model to Support Prognostic Decisions for Micro- and Macrovascular Complications of Type 2 Diabetes Mellitus. Journal of Medical Systems, 2019, 43, 185.	3.6	19
24	Evaluation of the use of clinical decision support and online resources for pharmacogenomics education. Pharmacogenomics, 2015, 16, 1595-1603.	1.3	18
25	Providers' Response to Clinical Decision Support for QT Prolonging Drugs. Journal of Medical Systems, 2017, 41, 161.	3.6	18
26	An Implementation Science Framework to Develop a Clinical Decision Support Tool for Familial Hypercholesterolemia. Journal of Personalized Medicine, 2020, 10, 67.	2.5	15
27	Genomic considerations for FHIR®; eMERGE implementation lessons. Journal of Biomedical Informatics, 2021, 118, 103795.	4.3	15
28	Pharmacogenomics education and perceptions: is there a gap between internal medicine resident and attending physicians?. Pharmacogenomics, 2021, 22, 195-201.	1.3	13
29	<p>Concepts Driving Pharmacogenomics Implementation Into Everyday Healthcare</p> . Pharmacogenomics and Personalized Medicine, 2019, Volume 12, 305-318.	0.7	12
30	Predicting diabetes clinical outcomes using longitudinal risk factor trajectories. BMC Medical Informatics and Decision Making, 2020, 20, 6.	3.0	9
31	Automated Tâ€wave analysis can differentiate acquired <scp>QT</scp> prolongation from congenital long <scp>QT</scp> syndrome. Annals of Noninvasive Electrocardiology, 2017, 22, .	1.1	8
32	Development and Validation of a Risk Stratification Model Using Disease Severity Hierarchy for Mortality or Major Cardiovascular Event. JAMA Network Open, 2020, 3, e208270.	5.9	8
33	Association of BMI, comorbidities and all-cause mortality by using a baseline mortality risk model. PLoS ONE, 2021, 16, e0253696.	2.5	8
34	Establishing an interdisciplinary research team for cardio-oncology artificial intelligence informatics precision and health equity. American Heart Journal Plus, 2022, 13, 100094.	0.6	8
35	Frequency and Cause of Transient QT Prolongation After Surgery. American Journal of Cardiology, 2015, 116, 1605-1609.	1.6	7
36	Evaluation of prescriber responses to pharmacogenomics clinical decision support for thiopurine <i>S</i> -methyltransferase testing. American Journal of Health-System Pharmacy, 2018, 75, 191-198	1.0	7

PEDRO J CARABALLO

#	Article	IF	CITATIONS
37	Challenges in returning results in a genomic medicine implementation study: the Return of Actionable Variants Empirical (RAVE) study. Npj Genomic Medicine, 2020, 5, 19.	3.8	7
38	A Computational Method for Learning Disease Trajectories From Partially Observable EHR Data. IEEE Journal of Biomedical and Health Informatics, 2021, 25, 2476-2486.	6.3	6
39	A novel method for causal structure discovery from EHR data and its application to type-2 diabetes mellitus. Scientific Reports, 2021, 11, 21025.	3.3	6
40	Phenotype of Children with QT Prolongation Identified Using an Institution-Wide QT Alert System. Pediatric Cardiology, 2015, 36, 1350-1356.	1.3	5
41	Decline in ACEI/ARB Prescribing as Heart Failure Core Metrics Improve During Computer-Based Clinical Decision Support. American Journal of Medical Quality, 2014, 29, 300-307.	0.5	4
42	Deploying Clinical Decision Support for Familial Hypercholesterolemia. ACI Open, 2020, 04, e157-e161.	0.5	4
43	Clinical Recognition and Management of Patients with Prediabetes. Endocrine Practice, 2019, 25, 545-553.	2.1	3
44	Frequent Causal Pattern Mining: A Computationally Efficient Framework For Estimating Bias-Corrected Effects. , 2019, 2019, 1981-1990.		3
45	Preferences for Updates on General Research Results: A Survey of Participants in Genomic Research from Two Institutions. Journal of Personalized Medicine, 2021, 11, 399.	2.5	3
46	Evaluating the Impact of Data Representation on EHR-Based Analytic Tasks. Studies in Health Technology and Informatics, 2019, 264, 288-292.	0.3	3
47	Estimating Disease Onset Time by Modeling Lab Result Trajectories via Bayes Networks. , 2017, 2017, 374-379.		2
48	Pharmacogenomics testing in patients with liver transplant and potential impact on prospective management. Pharmacogenomics, 2021, 22, 1177-1183.	1.3	2
49	Improving Recognition, Diagnosis, and Management Of Heparin Induced Thrombocytopenia By Implementing a Computer-Based Clinical Decision Support System. Blood, 2013, 122, 2966-2966.	1.4	1
50	Translating Pharmacogenomic Research to Therapeutic Potentials (Bench to Bedside). , 2021, , .		0